- Home
- LPTX vs PHIO Comparison
LPTX vs PHIO Comparison
Compare LPTX & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- PHIO
- Stock Information
- Founded
- LPTX 2011
- PHIO 2011
- Country
- LPTX United States
- PHIO United States
- Employees
- LPTX N/A
- PHIO 5
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- PHIO Health Care
- Exchange
- LPTX Nasdaq
- PHIO Nasdaq
- Market Cap
- LPTX 11.1M
- PHIO 12.1M
- IPO Year
- LPTX N/A
- PHIO N/A
- Fundamental
- Price
- LPTX $0.29
- PHIO $2.08
- Analyst Decision
- LPTX Hold
- PHIO Strong Buy
- Analyst Count
- LPTX 1
- PHIO 3
- Target Price
- LPTX N/A
- PHIO $10.67
- AVG Volume (30 Days)
- LPTX 2.0M
- PHIO 149.0K
- Earning Date
- LPTX 08-14-2025
- PHIO 08-14-2025
- Dividend Yield
- LPTX N/A
- PHIO N/A
- EPS Growth
- LPTX N/A
- PHIO N/A
- EPS
- LPTX N/A
- PHIO N/A
- Revenue
- LPTX N/A
- PHIO N/A
- Revenue This Year
- LPTX N/A
- PHIO N/A
- Revenue Next Year
- LPTX N/A
- PHIO N/A
- P/E Ratio
- LPTX N/A
- PHIO N/A
- Revenue Growth
- LPTX N/A
- PHIO N/A
- 52 Week Low
- LPTX $0.22
- PHIO $0.97
- 52 Week High
- LPTX $4.79
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- LPTX 46.11
- PHIO 44.74
- Support Level
- LPTX $0.28
- PHIO $1.96
- Resistance Level
- LPTX $0.31
- PHIO $2.13
- Average True Range (ATR)
- LPTX 0.04
- PHIO 0.12
- MACD
- LPTX 0.00
- PHIO 0.01
- Stochastic Oscillator
- LPTX 39.39
- PHIO 45.33
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.